Today's Portrait Highlights

Vilnius University Life Sciences Center

Vilnius University (VU) is the largest Lithuanian education and scientific institution. Research in Life and Health Sciences at VU is carried out in the Centre of Life Sciences. Research focus in the Centre of Life Sciences: gene editing technologies, like CRISPR Cas; nucleic acid and protein technologies, molecular diagnostics; drug design; droplet microfluidics technology; next generation epigenomics; biocatalyzers; lipid systems and membrane proteins; brain studies, like recording and analysis of physiological and psychophysiological parameters, also parameters of EEG, ECG, EDA, eye movements, psychological tests, steroid hormone concentration. Most of the Centre of Life Sciences laboratories are working as open access laboratories. Keywords: biomedicine; gene editing; epigenomics; biocatalyzers; diagnostic test systems; brain studies

Latvia Health Care, Green Tech and Life Science sectors

The Latvian healthcare sector has large healthcare centers to provide comprehensive health services. There are many opportunities due to its high growth rate and relatively low expenditure compared to the European Union average. Latvia is a leading European country in terms of specialization in renewable energy sources. Hydropower accounts for the largest source while biomass and biofuel are increasingly used in co-generating electricity and heat. The life sciences sector has experienced high growth in value added both in pharmaceuticals and medical devices. The R&D on red biotechnologies, white biotechnologies and green biotechnologies pharmaceuticals has a high growth potential.

Selvita

Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious and safe drugs to the market. Selvita Group laboratories have the General Pharmaceutical Inspectorate accreditation and Good Laboratory Practice (GLP) certification. Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Our current projects are in the area of oncology, central nervous system and autoimmune diseases.